Fedratinib (INREBIC®) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. It was approved for the first time in the United States in August 2019 to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycytha...
Open access
Research Article10.9734/jpri/2022/v34i38B36226
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gaine...
Open access
Research Article10.9734/jpri/2021/v33i44A32633
The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting...
Open access
Research Article10.9734/jpri/2022/v34i3B35387
A simple, Precise, Accurate method was developed for the estimation of Cenobamate by RP-HPLC technique. Chromatographic conditions used are stationary phase symmetry C18 (150 mm* 4.6 mm 5 µm), mobile phase Acetonitrile: 0.01NKH2PO4in the ratio of 55:45 and flow rate was maintai...
Open access
Research Article10.9734/jpri/2021/v33i46A32848